Biyapay
About Us
Corporate Profile
Management Team
Milestones
Awards
Our Vision
Affiliates
CTTQ Akesobio
Akeso Pharma
AD Pharmaceuticals
Contact Us
R&D and science
Technology Platform
Products Center
R&D and Manufacturing
Expanded Access Policy
Collaborations
Investor Relations
Financial Reports
Presentations
IR Monthly Reports
Announcements and Circulars
Corporate Governance
IR Calendar
IR Contact
Media
Akeso News
Media Coverage
Career
Social Recruitment
Campus Recruitment
简
|
EN
|
2021-06-21
Akeso among “TOP 10 Chinese Bispecific Antibody Drug Companies” Ranked by BioChina List of China Biopharmaceuticals
2021-06-18
Akeso Dr. Xia Yu and Dr. Wang Zhongmin Win the First “World-Benefiting Pharmaceutical Innovation” Award
2021-06-16
Out-Licensed by Akeso to MSD for US$200 Million, Monoclonal Antibody CTLA-4 Entered Phase III Clinical Trial
2021-06-15
ASCO21 | Latest Updates on Two Akeso’s AK104 (PD-1/CTLA-4 Bispecific Antibody) Clinical Trials
2021-06-11
Akeso Expands Development with New International Center Project Settles in Shanghai
2021-05-24
Akeso Penpulimab Monoclonal Antibody (PD-1) Submitted BLA in the United States
2021-05-20
Latest Updates on the Clinical Trials of AK104, AK112, AK117 and AK105 Published at ASCO 2021
2021-05-18
CD47 Monoclonal Antibody (AK117) Obtained Approval for Phase I/II Clinical Trial for Treatment of Medium- to High-Risk Myelodysplastic Syndromes (MDS)
2021-05-13
Akeso, Inc. Inclusion in the MSCI China Index
2021-05-12
Initiation of Various Clinical Trials of PD-1/VEGF Bispecific Antibody (AK112)
2021-04-28
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Obtained Approval to Initiate Phase III Clinical Trial for First-Line Treatment of Advanced Cervical Cancer
2021-04-27
New Level of Production Capacity Expansion Akeso Builds the World’s Largest FlexFactory Platform in Cooperation with Cytiva
«
8
9
10
11
12
13
14
15
16
»
